Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2026)

Altimmune's (ALT) quarterly Asset Writedowns and Impairment came in at $709000.0 in Q1 2026, down 78.52% on a QoQ basis from $3.3 million in Q4 2021.

Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends

Altimmune (ALT) has 5 years of Asset Writedowns and Impairment data on file, last reported at $709000.0 in Q1 2026.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $709000.0 in Q1 2026; TTM through Mar 2026 was $12.1 million, a N/A change from a year earlier, with the FY2023 full-year figure at $12.4 million, changed N/A from the prior year.
Asset Writedowns and Impairment for Q1 2026 stood at $709000.0, down from $3.3 million in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for ALT reached as high as $709000.0 in Q1 2026 and fell as low as $709000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Altimmune	7.96 Mn	7.96 Mn	-

Download Data